Anti-IL5 and anti-IL5Rα therapy for clinically significant bronchiectasis with eosinophilic endotype: a case series

a) Forced expiratory volume in 1 s (FEV₁); b) annualised exacerbation frequency; c) modified Medical Research Council (mMRC) dyspnoea scale; d) quality of life (QoL); e) eosinophils; and f) 24-h sputum volume at baseline and after 3 and 6 months of treatment. VAS: visual analogue scale.